Product logins

Find logins to all Clarivate products below.


John Lebbos

Partner, Commercial Strategy Consulting

John Lebbos, MD is a Partner in Clarivate’s Commercial Strategy Consulting team.​​​

He is currently a practice leader in Product and Market Opportunity Assessments & Strategy and has over 20 years of experience supporting clients with product and therapeutic area strategy, functional patient journey analysis, opportunity and market assessments, disease area analysis, sales forecasting, and portfolio planning/strategy.​​

Formerly a Vice President in DRG’s infectious disease syndicated research group, Dr. Lebbos led the Infectious Disease research team and has had over 20 years of experience conducting market analysis, opportunity assessments and prioritization and product strategy. ​​

Dr. Lebbos received his medical degree from the University of Massachusetts. Prior to pursuing his medical degree, he attended Tufts University where he graduated summa cum laude in chemical engineering.


arrow_forward
Get in touch with John

Related resources

应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
Relacorilant:当证据满足既定证据标准时 Relacorilant:当证据满足既定证据标准时
Blog February 24, 2026
Relacorilant:当证据满足既定证据标准时
FDA 临床试验 市场准入 最值得关注的药物 真实世界数据 美国市场 药政法规
Tolebrutinib:当安全性隐忧掩盖疗效信号 Tolebrutinib:当安全性隐忧掩盖疗效信号
Blog February 24, 2026
Tolebrutinib:当安全性隐忧掩盖疗效信号
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规 药物安全